We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oversight of opioid advertising in Canada remains lax despite new federal guidance.
- Authors
Webster, Paul
- Abstract
The article reports the lax oversight of opioid advertising in Canada despite the launching by Health Canada of new federal guidelines as of June 2018. Also cited are the comments of Ray Chepesiuk of Pharmaceutical Advertising Advisory Board and Health Canada's Eric Morrissette on the issue, as well as the advertising review made by Innovative Medicines Canada.
- Subjects
CANADA; OPIOIDS; ANTI-drug advertising; GOVERNMENT policy on advertising; CANADA. Health Canada; INNOVATIVE Medicines Canada (Company); GOVERNMENT policy; ADVERTISING laws; INDUSTRIAL laws &; legislation; ANALGESICS; DRUG utilization; FEDERAL government; MEDICAL protocols; NARCOTICS; PUBLIC health; GOVERNMENT regulation
- Publication
Canadian Medical Association Journal (CMAJ), 2018, Vol 190, Issue 23, pE730
- Publication type
journal article
- DOI
10.1503/cmaj.109-5612